



DEPARTMENT OF PHARMACOLOGY

NEW DRUG UPDATE

Series No: 69, MARCH, 2025

S.N O	DRUG & APPROVAL DATE	MECHANISM	INDICATION	DOSAGE FORMS
1.	Revakinagene taroretcel-lwey 5/3/25	Recombinant ciliary neurotrophic factor (rhCNTF), a potent neuroprotective protein that promotes the survival and maintenance of photoreceptors.	Idiopathic macular telangiectasia type 2	Intravitreal Implant
2.	Omalizumab-igec 7/3/25	Anti-IgE antibody	Asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and urticaria.	Subcutaneous Injection
3.	Losartan potassium 13/3/25	Angiotensin II receptor blocker	Hypertension and diabetic nephropathy.	Oral Suspension
4.	Gallium Ga 68 Gozetotide 20/3/25	Radioactive diagnostic agent	Positron Emission Tomography Imaging	Intravenous bolus injection.
5.	Denosumab-bnht 25/3/25	RANK ligand (RANKL) inhibitor	Osteolytic Bone Lesions of Multiple Myeloma, Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy, Osteoporosis	Subcutaneous Injection



6.	Gepotidacin 25/3/25	Bacterial type II topoisomerase inhibitor	Uncomplicated urinary tract infections.	Tablets
7.	Diazoxide choline 26/3/25	Activating ATP-sensitive potassium channels (KATP channels)	Hyperphagia in patients with Prader-Willi syndrome	Extended-Release Tablets
8.	Fitusiran 28/3/25	Antithrombin-direct ed- small interfering RNA (siRNA)	Hemophilia A or B with or without factor VIII or IX inhibitors.	Subcutaneous Injection

Contact Details:

Email your suggestions to : hodpharmacology@kmchihsr.edu.in

Website : <http://www.kmchihsr.edu.in>